Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2010 Feb 17

PMID 20156921

Citations 130

Authors

Faryal S Mirza

I Desmond Padhi

Lawrence G Raisz

Joseph A Lorenzo

Affiliations

Soon will be listed here.

Abstract

Context: Sclerostin is a negative regulator of bone formation.

Objective: The aim of the study was to compare serum sclerostin levels in premenopausal and postmenopausal women and evaluate its relationship to estrogen, TH, bone turnover, and bone mass.

Design, Setting, And Participants: We conducted a cross-sectional observational study of healthy community-dwelling pre- and postmenopausal women.

Intervention(s): There were no interventions.

Main Outcome Measure(s): We compared serum sclerostin levels in pre- and postmenopausal women and correlated sclerostin levels with female sex hormones, calciotropic hormones, bone turnover markers, and bone mineral density.

Results: Premenopausal women were 26.8 yr old, and postmenopausal women were 56.8 yr old. Postmenopausal women had lower values for estradiol (30 +/- 23 vs. 10 +/- 4 pg/ml; P < 0.001), estrone (61 +/- 24 vs. 29 +/- 10 pg/ml; P <0.001), and free estrogen index (FEI) (6 +/- 4 vs. 3 +/- 2 pmol/nmol; P = 0.008) and significantly lower bone mineral density at all sites compared to premenopausal women, with no significant differences in levels of PTH, 25-hydroxy or 1,25-dihydroxy vitamin D levels. Postmenopausal women had significantly higher serum sclerostin levels (1.16 +/- 0.38 ng/ml vs. 0.48 +/- 0.15 ng/ml; P < 0.001). Because most of the premenopausal women were on oral contraceptives, subsequent analyses were limited to postmenopausal women. There were significant negative correlations between sclerostin and FEI and sclerostin and PTH in this group. Using multiple regression analysis, both FEI (beta = -0.629; P = 0.002) and PTH (beta = -0.554; P = 0.004) were found to be independent predictors of sclerostin levels in postmenopausal women.

Conclusions: Our findings suggest that serum sclerostin levels are regulated by both estrogens and PTH in postmenopausal women. These findings need to be explored further in larger prospective studies.

Citing Articles

Role of sclerostin in mastocytosis bone disease.

Szudy-Szczyrek A, Mlak R, Pigon-Zajac D, Krupski W, Mazurek M, Tomczak A Sci Rep. 2025; 15(1):161.

PMID: 39747949 PMC: 11697018. DOI: 10.1038/s41598-024-83851-0.

Sclerostin and Wnt Signaling in Idiopathic Juvenile Osteoporosis Using High-Resolution Confocal Microscopy for Three-Dimensional Analyses.

Pereira R, Noche K, Gales B, Chen Z, Salusky I, Albrecht L Children (Basel). 2024; 11(7).

PMID: 39062269 PMC: 11276078. DOI: 10.3390/children11070820.

PTH receptor signalling, osteocytes and bone disease induced by diabetes mellitus.

Marino S, Bellido T Nat Rev Endocrinol. 2024; 20(11):661-672.

PMID: 39020007 DOI: 10.1038/s41574-024-01014-7.

Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease.

Hu L, Chen W, Qian A, Li Y Bone Res. 2024; 12(1):39.

PMID: 38987555 PMC: 11237130. DOI: 10.1038/s41413-024-00342-8.

Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer's disease progression.

Shi T, Shen S, Shi Y, Wang Q, Zhang G, Lin J Nat Metab. 2024; 6(3):531-549.

PMID: 38409606 DOI: 10.1038/s42255-024-00989-x.

References

Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860-9. DOI: 10.1359/jbmr.080216. View

Semenov M, Tamai K, He X . SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280(29):26770-5. DOI: 10.1074/jbc.M504308200. View

Johnson M, Kamel M . The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol. 2007; 19(4):376-82. DOI: 10.1097/BOR.0b013e32816e06f9. View

Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23):6267-76. PMC: 291840. DOI: 10.1093/emboj/cdg599. View

Stein S, Witkop C, Hill S, Fallon M, Viernstein L, Gucer G . Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology. 1983; 33(3):267-77. DOI: 10.1212/wnl.33.3.267. View

He X, Semenov M, Tamai K, Zeng X . LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development. 2004; 131(8):1663-77. DOI: 10.1242/dev.01117. View

Riggs B, Khosla S, Melton 3rd L . A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998; 13(5):763-73. DOI: 10.1359/jbmr.1998.13.5.763. View

Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S . BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 2003; 18(10):1842-53. DOI: 10.1359/jbmr.2003.18.10.1842. View

Eriksen E, Mosekilde L, Melsen F . Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone. 1986; 7(3):213-21. DOI: 10.1016/8756-3282(86)90020-7. View

10.

Spencer G, Utting J, Etheridge S, Arnett T, Genever P . Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci. 2006; 119(Pt 7):1283-96. DOI: 10.1242/jcs.02883. View

11.

van Bezooijen R, Roelen B, Visser A, van der Wee-Pals L, de Wilt E, Karperien M . Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199(6):805-14. PMC: 2212719. DOI: 10.1084/jem.20031454. View

12.

Li X, Ominsky M, Warmington K, Morony S, Gong J, Cao J . Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2008; 24(4):578-88. DOI: 10.1359/jbmr.081206. View

13.

Baron R, Rawadi G . Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007; 5(2):73-80. DOI: 10.1007/s11914-007-0006-0. View

14.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

15.

Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

16.

Yavropoulou M, Yovos J . The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens). 2007; 6(4):279-94. DOI: 10.14310/horm.2002.1111024. View

17.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M . Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537-43. DOI: 10.1093/hmg/10.5.537. View

18.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

19.

Day T, Guo X, Garrett-Beal L, Yang Y . Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005; 8(5):739-50. DOI: 10.1016/j.devcel.2005.03.016. View

20.

Ellies D, Viviano B, McCarthy J, Rey J, Itasaki N, Saunders S . Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006; 21(11):1738-49. DOI: 10.1359/jbmr.060810. View